(VIANEWS) – Eton Pharmaceuticals (ETON), Genmab (GMAB), Laureate Education (LAUR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eton Pharmaceuticals (ETON)
56.5% sales growth and 15.9% return on equity
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Earnings Per Share
As for profitability, Eton Pharmaceuticals has a trailing twelve months EPS of $0.09.
PE Ratio
Eton Pharmaceuticals has a trailing twelve months price to earnings ratio of 45.33. Meaning, the purchaser of the share is investing $45.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.9%.
2. Genmab (GMAB)
41.8% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.94.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 29.78. Meaning, the purchaser of the share is investing $29.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
Sales Growth
Genmab’s sales growth is negative 5.3% for the present quarter and 41.8% for the next.
Moving Average
Genmab’s value is under its 50-day moving average of $31.10 and way under its 200-day moving average of $35.83.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Genmab’s EBITDA is 7.3.
3. Laureate Education (LAUR)
11.7% sales growth and 11.36% return on equity
Laureate Education, Inc., together with its subsidiaries, provides higher education programs and services to students through a network of universities and higher education institutions. It offers a range of undergraduate and graduate degree programs primarily in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. The company provides its services in Brazil, Mexico, Chile, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. The company was founded in 1989 and is headquartered in Baltimore, Maryland.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.65.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 19.55. Meaning, the purchaser of the share is investing $19.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.36%.
Volume
Today’s last reported volume for Laureate Education is 599592 which is 18.53% below its average volume of 736031.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.1%, now sitting on 1.42B for the twelve trailing months.
4. Darden Restaurants (DRI)
9.2% sales growth and 49.72% return on equity
Darden Restaurants, Inc., together with its subsidiaries, owns and operates full-service restaurants in the United States and Canada. It operates under Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Yard House, The Capital Grille, Seasons 52, Bahama Breeze, Eddie V's Prime Seafood, and Capital Burger brand names. Darden Restaurants, Inc. was incorporated in 1995 and is based in Orlando, Florida.
Earnings Per Share
As for profitability, Darden Restaurants has a trailing twelve months EPS of $8.26.
PE Ratio
Darden Restaurants has a trailing twelve months price to earnings ratio of 20.23. Meaning, the purchaser of the share is investing $20.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.72%.
5. Bright Horizons Family Solutions (BFAM)
9.1% sales growth and 8.03% return on equity
Bright Horizons Family Solutions Inc. provides child care and early education services, back-up care services, educational advisory services, and other workplace solutions for employers and families. The company operates through three segments: Full Service Center-Based Child Care, Back-Up Care, and Educational Advisory and Other Services. The Full Service Center-Based Child Care segment offers traditional center-based child care and early education, preschool, and elementary education services. The Back-Up Care segment provides center-based back-up child care, in-home child and adult/elder dependent care, and self-sourced reimbursed care services. The Educational Advisory and Other Services segment offers tuition assistance and student loan repayment program administration, workforce education, and related educational consulting services, as well as college admissions advisory services. As of December 31, 2020, it operated 1,014 child care and early education centers in the United States, Puerto Rico, the United Kingdom, Canada, the Netherlands, and India. The company was formerly known as Bright Horizons Solutions Corp. and changed its name to Bright Horizons Family Solutions Inc. in July 2012. Bright Horizons Family Solutions Inc. was founded in 1986 and is headquartered in Newton, Massachusetts.
Earnings Per Share
As for profitability, Bright Horizons Family Solutions has a trailing twelve months EPS of $1.49.
PE Ratio
Bright Horizons Family Solutions has a trailing twelve months price to earnings ratio of 67.4. Meaning, the purchaser of the share is investing $67.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.03%.
Yearly Top and Bottom Value
Bright Horizons Family Solutions’s stock is valued at $100.43 at 15:22 EST, below its 52-week high of $100.94 and way higher than its 52-week low of $71.65.
Sales Growth
Bright Horizons Family Solutions’s sales growth is 12.2% for the present quarter and 9.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Bright Horizons Family Solutions’s EBITDA is 69.96.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 5.2% and positive 8.2% for the next.
6. Webster Financial Corporation (WBS)
7.1% sales growth and 10.36% return on equity
Webster Financial Corporation operates as the bank holding company for Webster Bank, National Association that provides a range of financial services to individuals, families, and businesses in the United States. It operates through three segments: Commercial Banking, HSA Bank, and Consumer Banking. The Commercial Banking segment provides commercial real estate and equipment financing, business banking, asset-based lending, and commercial services; public sector finance; mortgage warehouse financing; treasury management services; credit, deposit, and cash flow management services; and wealth management solutions to business owners and operators, including trust, asset management, financial planning, insurance, retirement, and investment products, as well as derivative, treasury, accounts payable, accounts receivable, and trade products and services. The HSA Bank segment offers health savings accounts, health reimbursement arrangements, flexible spending accounts, and commuter services that are distributed directly to employers and individual consumers, as well as through national and regional insurance carriers, consultants, and financial advisors. The Consumer Banking segment provides consumer deposit and fee-based services, residential mortgages, home equity lines, secured and unsecured loans, and credit cards to consumers; and small business banking products, such as credit, deposit, and cash flow management to businesses and professional service firms. It also offers online and mobile banking services. Webster Financial Corporation was founded in 1935 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Webster Financial Corporation has a trailing twelve months EPS of $4.91.
PE Ratio
Webster Financial Corporation has a trailing twelve months price to earnings ratio of 10.43. Meaning, the purchaser of the share is investing $10.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.36%.
Yearly Top and Bottom Value
Webster Financial Corporation’s stock is valued at $51.21 at 15:22 EST, below its 52-week high of $56.00 and way above its 52-week low of $31.03.
Sales Growth
Webster Financial Corporation’s sales growth is 0.8% for the ongoing quarter and 7.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 4% and a negative 3.3%, respectively.
Previous days news about Webster Financial Corporation(WBS)
- According to Zacks on Wednesday, 31 January, "Last week, Webster Financial Corporation (WBS Quick QuoteWBS – Free Report) completed the acquisition of Ametros Financial Corp, to broaden its financial services portfolio. "
7. Cemex, S.A.B. de C.V. Sponsored ADR (CX)
6.6% sales growth and 3.99% return on equity
CEMEX, S.A.B. de C.V., together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, clinker, and other construction materials worldwide. The company also offers various complementary construction products, including asphalt products; concrete blocks; roof tiles; architectural products; concrete pipes for storm and sanitary sewers applications; and other precast products, such as rail products, concrete floors, box culverts, bridges, drainage basins, barriers, and parking curbs. In addition, it provides building solutions for housing projects, pavement projects, and green building consultancy services; cement trade maritime services; and information technology solutions. The company operates approximately 2,000 retail stores in approximately 600 cities. CEMEX, S.A.B. de C.V. was founded in 1906 and is headquartered in San Pedro Garza GarcÃa, Mexico.
Earnings Per Share
As for profitability, Cemex, S.A.B. de C.V. Sponsored ADR has a trailing twelve months EPS of $-1.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.99%.
Yearly Top and Bottom Value
Cemex, S.A.B. de C.V. Sponsored ADR’s stock is valued at $7.51 at 15:22 EST, way below its 52-week high of $8.46 and way above its 52-week low of $4.72.
